Health
Merck Faces Patent Lawsuit Over Easier-to-Use Keytruda
Merck headquarters in Rahway, New Jersey.
Photographer: Christopher Occhicone/BloombergThis article is for subscribers only.
A biotech company is suing Merck & Co. over its easier-to-use version of its blockbuster cancer treatment Keytruda, alleging the pharmaceutical giant violated its intellectual property.
Merck knowingly infringed Halozyme Therapeutics Inc.’s patents in crafting a version of Keytruda that can be administered as a shot rather than through an intravenous infusion, according to a lawsuit filed in the US District Court for the District of New Jersey on Thursday.